ASH 2026 guidelines for relapsed/refractory acute lymphoblastic leukaemia in adolescents and young adults make 8 recommendations, including blinatumomab and/or inotuzumab over chemotherapy for reinduction, and cover CNS relapse, T-cell ALL and transplant consolidation.
Guideline
O'Dwyer et al. American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults